Edwards Stock Analysis

EW Stock  USD 80.92  0.16  0.20%   
The latest indifference towards the small price fluctuations of Edwards Lifesciences Corp could raise concerns from sophisticated investors as the firm is trading at a share price of 80.92 on 2,914,374 in volume. The company executives did not add any value to Edwards Lifesciences investors in February. However, most investors can still diversify their portfolios with Edwards Lifesciences Corp to hedge their inherited risk against high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 2.13. The current volatility is consistent with the ongoing market swings in February 2023 as well as with Edwards Lifesciences unsystematic, company-specific events.
Check out Investing Opportunities. For more information on how to buy Edwards Stock please use our How to Invest in Edwards Lifesciences guide.
The main objective of Edwards Lifesciences stock analysis is to determine its intrinsic value, which is an estimate of what Edwards Lifesciences Corp is worth, separate from its market price. There are two main types of Edwards Lifesciences' stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect Edwards Lifesciences' performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of Edwards Lifesciences' stock to identify patterns and trends that may indicate its future price movements.
The Edwards Lifesciences stock is traded in the USA on New York Stock Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Edwards Lifesciences is usually not traded on Thanksgiving Day, Christmas Day, Christmas Day ( substitute day ), New Year 's Monday, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. Edwards Stock trading window is adjusted to America/New York timezone. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Edwards Lifesciences' ongoing operational relationships across important fundamental and technical indicators.

Edwards Stock Analysis Notes

About 87.0% of the company shares are held by institutions such as insurance companies. The company had not issued any dividends in recent years. Edwards Lifesciences Corp had 3:1 split on the 1st of June 2020. Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California. Edwards Lifesciences operates under Medical Devices classification in the United States and is traded on New York Stock Exchange. It employs 15700 people. To learn more about Edwards Lifesciences Corp call Michael Mussallem at 949 250-2500 or check out www.edwards.com.

Edwards Lifesciences Quarterly Cost of Revenue

257.9 Million

Edwards Lifesciences Corp Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Edwards Lifesciences' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Edwards Lifesciences Corp or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Edwards Lifesciences is unlikely to experience financial distress in the next 2 years
Edwards Lifesciences has a strong financial position based on the latest SEC filings
Over 87.0% of the company shares are held by institutions such as insurance companies
Latest headline from finance.yahoo.com: ReShape Lifesciences Announces Formation of International Scientific Advisory Board

Edwards Lifesciences Corp Upcoming and Recent Events

Earnings reports are used by Edwards Lifesciences to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Edwards Lifesciences previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
25th of April 2023
Upcoming Quarterly Report
27th of July 2023
Next Financial Report
31st of March 2023
Next Fiscal Quarter End
30th of January 2024
Next Fiscal Year End
31st of December 2022
Last Quarter Report
31st of December 2022
Last Financial Announcement

Edwards Largest EPS Surprises

Earnings surprises can significantly impact Edwards Lifesciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Fiscal Date
Estimated EPS
Reported EPS
View All Earnings Estimates
View All Earnings Estimates

Edwards Lifesciences SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Edwards Lifesciences prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Edwards Lifesciences investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Edwards Lifesciences Corp specific information freely available to individual and institutional investors to make a timely investment decision.
21st of February 2023
Financial Statements and Exhibits. Amendments to Articles of Incorporation or Bylaws; and/or Change in Fiscal Year
9th of February 2023
Unclassified Corporate Event
7th of February 2023
Unclassified Corporate Event
31st of January 2023
Financial Statements and Exhibits. Results of Operations and Financial Condition
8th of December 2022
Financial Statements and Exhibits. Regulation FD Disclosure. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
1st of November 2022
Financial Statements and Exhibits. Other Events
27th of October 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
28th of July 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition

Edwards Lifesciences Thematic Classifications

In addition to having Edwards Lifesciences stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Obamacare Repeal Idea
Obamacare Repeal
Large healthcare related equities associated with Obamacare
Medical Equipment Idea
Medical Equipment
USA Equities from Medical Equipment industry as classified by Fama & French
Macroaxis Picks Idea
Macroaxis Picks
Macroaxis daily picks
Healthcare Idea
USA Equities from Healthcare industry as classified by Fama & French

Edwards Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Edwards Lifesciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Edwards Lifesciences Corp backward and forwards among themselves. Edwards Lifesciences' institutional investor refers to the entity that pools money to purchase Edwards Lifesciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Last TransactionTypeSharesValue
Vanguard Group Inc2022-12-31Common Shares51.6 M3.8 B
State Street Corp2022-12-31Common Shares27.3 MB
Wellington Management Group Llp2022-12-31Common Shares15.3 M1.1 B
Norges Bank2022-12-31Common Shares8.8 M658.4 M
Sands Capital Management Llc2022-12-31Common Shares7.5 M560.8 M
Morgan Stanley2022-12-31Common Shares7.2 M536 M
Northern Trust Corp2022-12-31Common Shares6.5 M487.5 M
Nuveen Asset Management Llc2022-12-31Common Shares5.4 M404.3 M
Royal Bank Of Canada2022-12-31Common Shares4.8 M359.4 M
Ownership Capital Bv2022-12-31Common Shares4.2 M310 M
Parametric Portfolio Associates Llc2022-03-31Common Shares2.6 M300.7 M
Note, although Edwards Lifesciences' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Edwards Market Capitalization

The company currently falls under 'Large-Cap' category with a market capitalization of 49.13 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Edwards Lifesciences's market, we take the total number of its shares issued and multiply it by Edwards Lifesciences's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Edwards Profitablity

Edwards Lifesciences' profitability indicators refer to fundamental financial ratios that showcase Edwards Lifesciences' ability to generate income relative to its revenue or operating costs. If, let's say, Edwards Lifesciences is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Edwards Lifesciences' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Edwards Lifesciences' profitability requires more research than a typical breakdown of Edwards Lifesciences' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Net Profit Margin (PM) of 0.28 %, which suggests that even a small decline in it sales will erase profits and may result in a net loss, or a negative profit margin. This is way below average. Likewise, it shows Net Operating Margin (NOM) of 0.33 %, which signifies that for every $100 of sales, it has a net operating income of $0.33.
Last ReportedProjected for 2023
Return on Investment 27.25  25.11 
Return on Average Assets 0.18  0.20 
Return on Average Equity 0.26  0.24 
Return on Invested Capital 0.32  0.34 
Return on Sales 0.33  0.34 

Management Efficiency

The entity has Return on Asset (ROA) of 0.1334 % which means that for every $100 of asset, it generated profit of $0.1334. This is way below average. Likewise, it shows return on total equity (ROE) of 0.2614 %, which means that it produced $0.2614 on every 100 dollars invested by current stockholders. Edwards Lifesciences management efficiency ratios could be used to measure how well edwards lifesciences corp manages its routine affairs as well as how well it operates its assets and liabilities. Edwards Lifesciences Return on Average Assets are fairly stable at the moment as compared to the past year. Edwards Lifesciences reported Return on Average Assets of 0.18 in 2022. Return on Invested Capital is likely to climb to 0.34 in 2023, whereas Return on Investment is likely to drop 25.11 in 2023. Edwards Lifesciences Tax Assets are fairly stable at the moment as compared to the past year. Edwards Lifesciences reported Tax Assets of 484 Million in 2022. Revenue to Assets is likely to climb to 0.75 in 2023, whereas Current Assets are likely to drop slightly above 3 B in 2023.
Last ReportedProjected for 2023
Book Value per Share 9.38  8.01 
Enterprise Value over EBIT 26.00  31.74 
Enterprise Value over EBITDA 23.33  28.52 
Price to Book Value 7.94  9.27 
Tangible Assets Book Value per Share 11.05  9.70 
Enterprise Value45.6 B42.7 B
Tangible Asset Value6.8 B6.1 B
The analysis of Edwards Lifesciences' management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Edwards Lifesciences' future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Edwards Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Long Term Debt Total
596.3 M
Non Current Liabilities Total
1.5 B
Short Long Term Debt Total
691.3 M
Interest Expense
16.3 M
Total Operating Expenses
2.5 B

Technical Drivers

As of the 27th of March, Edwards Lifesciences shows the Coefficient Of Variation of 10718.69, downside deviation of 2.35, and Mean Deviation of 1.52. Edwards Lifesciences Corp technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We are able to interpolate and break down nineteen technical drivers for Edwards Lifesciences Corp, which can be compared to its rivals. Please confirm Edwards Lifesciences Corp information ratio, potential upside, as well as the relationship between the Potential Upside and kurtosis to decide if Edwards Lifesciences Corp is priced favorably, providing market reflects its regular price of 80.92 per share. Given that Edwards Lifesciences has jensen alpha of 0.0226, we urge you to verify Edwards Lifesciences Corp's prevailing market performance to make sure the company can sustain itself at a future point.

Edwards Lifesciences Corp Price Movement Analysis

null. The output start index for this execution was zero with a total number of output elements of zero. The Triple Exponential Moving Average (T3) indicator is developed by Tim Tillson as Edwards Lifesciences Corp price series composite of a single exponential moving average, a double exponential moving average and a triple exponential moving average.

Edwards Lifesciences Corp Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Edwards Lifesciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Edwards Lifesciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Edwards Lifesciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Larry Wood over a month ago
Acquisition by Larry Wood of 3235 shares of Edwards Lifesciences subject to Rule 16b-3
Daveen Chopra over three months ago
Exercise or conversion by Daveen Chopra of 4000 shares of Edwards Lifesciences subject to Rule 16b-3
Larry Wood over three months ago
Exercise or conversion by Larry Wood of 7242 shares of Edwards Lifesciences subject to Rule 16b-3
Michael Mussallem over six months ago
Exercise or conversion by Michael Mussallem of 29375 shares of Edwards Lifesciences subject to Rule 16b-3
Donald Bobo over six months ago
Exercise or conversion by Donald Bobo of 6725 shares of Edwards Lifesciences subject to Rule 16b-3
Larry Wood over six months ago
Exercise or conversion by Larry Wood of 7242 shares of Edwards Lifesciences subject to Rule 16b-3
Larry Wood over six months ago
Exercise or conversion by Larry Wood of 7242 shares of Edwards Lifesciences subject to Rule 16b-3
Daveen Chopra over six months ago
Sale by Daveen Chopra of 1000 shares of Edwards Lifesciences
JeanLuc Lemercier over six months ago
Acquisition by JeanLuc Lemercier of 7625 shares of Edwards Lifesciences subject to Rule 16b-3
Huimin Wang over six months ago
Exercise or conversion by Huimin Wang of 3675 shares of Edwards Lifesciences subject to Rule 16b-3
Catherine Szyman over six months ago
Acquisition by Catherine Szyman of 2032 shares of Edwards Lifesciences subject to Rule 16b-3
Larry Wood over six months ago
Exercise or conversion by Larry Wood of 7242 shares of Edwards Lifesciences subject to Rule 16b-3

Edwards Lifesciences Outstanding Bonds

Edwards Lifesciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Edwards Lifesciences Corp uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Edwards bonds can be classified according to their maturity, which is the date when Edwards Lifesciences Corp has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Edwards Lifesciences Predictive Daily Indicators

Edwards Lifesciences intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Edwards Lifesciences stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Edwards Lifesciences Forecast Models

Edwards Lifesciences time-series forecasting models is one of many Edwards Lifesciences' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Edwards Lifesciences' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Edwards Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Edwards Lifesciences prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Edwards shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual Stock such as Edwards Lifesciences. By using and applying Edwards Stock analysis, traders can create a robust methodology for identifying Edwards entry and exit points for their positions.
Last ReportedProjected for 2023
Operating Margin 32.49  28.23 
EBITDA Margin 0.36  0.37 
Gross Margin 0.80  0.86 
Profit Margin 0.28  0.28 

Current Edwards Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Edwards analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Edwards analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
Edwards Lifesciences Corp current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Edwards analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Edwards stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Edwards Lifesciences Corp, talking to its executives and customers, or listening to Edwards conference calls.
Edwards Analyst Advice Details

Edwards Stock Analysis Indicators

Edwards Lifesciences Corp stock analysis indicators help investors evaluate how Edwards Lifesciences stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Edwards Lifesciences shares will generate the highest return on investment. By understating and applying Edwards Lifesciences stock analysis, traders can identify Edwards Lifesciences position entry and exit signals to maximize returns.
Begin Period Cash Flow867.4 M
Total Stockholder Equity5.8 B
Property Plant And Equipment Net1.7 B
Retained Earnings7.6 B
Cash And Short Term Investments1.2 B
Retained Earnings Total Equity7.6 B
Cash769 M
50 Day M A78.642
Net Interest Income16.3 M
Total Current LiabilitiesB
Forward Price Earnings30.1205
Common Stock Total Equity646.3 M
Stock Based Compensation126.8 M
Common Stock Shares Outstanding624.2 M
Total Cashflows From Investing Activities252.3 M
Tax Provision245.5 M
Quarterly Earnings Growth Y O Y0.227
Accounts Payable201.9 M
Net Debt-77.7 M
Other Operating Expenses3.6 B
Non Current Assets Total5.2 B
Liabilities And Stockholders Equity8.3 B
Non Currrent Assets Other299.1 M
Check out Investing Opportunities. For more information on how to buy Edwards Stock please use our How to Invest in Edwards Lifesciences guide. You can also try Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.

Complementary Tools for analysis

When running Edwards Lifesciences Corp price analysis, check to measure Edwards Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Edwards Lifesciences is operating at the current time. Most of Edwards Lifesciences' value examination focuses on studying past and present price action to predict the probability of Edwards Lifesciences' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Edwards Lifesciences' price. Additionally, you may evaluate how the addition of Edwards Lifesciences to your portfolios can decrease your overall portfolio volatility.
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Is Edwards Lifesciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Edwards Lifesciences. If investors know Edwards will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Edwards Lifesciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
Earnings Share
Revenue Per Share
Quarterly Revenue Growth
Return On Assets
The market value of Edwards Lifesciences Corp is measured differently than its book value, which is the value of Edwards that is recorded on the company's balance sheet. Investors also form their own opinion of Edwards Lifesciences' value that differs from its market value or its book value, called intrinsic value, which is Edwards Lifesciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Edwards Lifesciences' market value can be influenced by many factors that don't directly affect Edwards Lifesciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Edwards Lifesciences' value and its price as these two are different measures arrived at by different means. Investors typically determine Edwards Lifesciences value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Edwards Lifesciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.